Mirum Pharmaceuticals (MIRM) EBT (2019 - 2026)

Mirum Pharmaceuticals' EBT history runs 8 years deep, the most recent figure standing at -$789.7 million for Q1 2026.

• In Q1 2026, EBT fell 5686.05% year-over-year to -$789.7 million; the TTM figure through Mar 2026 stood at -$797.5 million (down 950.6% YoY), while the FY2025 annual figure was -$21.4 million, up 75.35% from the prior year.
• EBT for Q1 2026 stood at -$789.7 million, down from -$5.0 million in the prior quarter.
• The five-year high for EBT was $2.6 million in Q3 2025, with the low at -$789.7 million in Q1 2026.
• The 5-year median for EBT is -$24.7 million (2024), against an average of -$70.7 million.
• The sharpest annual moves came in 2025 and 2026: EBT surged 119.03% in 2025, then sank 5686.05% in 2026.
• Mirum Pharmaceuticals' EBT stood at -$36.3 million in 2022, then advanced by 2.36% to -$35.4 million in 2023, then surged by 31.24% to -$24.4 million in 2024, then jumped by 79.63% to -$5.0 million in 2025, then plunged by 15811.34% to -$789.7 million in 2026.
• Business Quant data shows MIRM's EBT at -$789.7 million in Q1 2026, -$5.0 million in Q4 2025, and $2.6 million in Q3 2025.